BioXcel Therapeutics Overview
Valuation check: BTAI's ROE is 61.37%, above the Healthcare sector average of 20.77%.
Get informed when a big investor buys or sells
+ Follow61.37%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
BioXcel Therapeutics (BTAI) currently reports a ROE of 61.37%. That is above the Healthcare sector average of 20.77%. Use the charts on this page to explore BioXcel Therapeutics's ROE history and peer comparisons.
BioXcel Therapeutics's ROE of 61.37% is higher than the Healthcare sector average of 20.77%. That is roughly 195.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but BioXcel Therapeutics's current 61.37% should be judged against Healthcare norms (sector average: 20.77%) and against BTAI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 61.37%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for BioXcel Therapeutics, and consider following BTAI for alerts when major investors trade the stock.
BioXcel Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 61.37% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BTAI with unrelated industries.
